In addition, it has been suggested that CREBBP mutation may lead to chemotherapy resistance via impaired histone acetylation and corresponding gene dysregulation, not only in hematologic tumors such as lymphoma and acute lymphoblastic leukemia [31, 32, 33], but also in various solid tumors such as breast cancer and small‐cell lung cancer [34, 35]. Here, CREBBP is linked to lymphoma.